Actinium Pharmaceuticals, Inc.
AMEX:ATNMBiotechnology
+$0.22 today
- Market cap
- $51.56M
- Beta
- 0.02
- P/E (TTM)
- 4.4
- EPS (TTM)
- $0.36
Volume 0.18M
Average 0.15M
ATNM Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Actinium Pharmaceuticals, Inc.AMEX: ATNM
Cash & Equivalents · Q2 FY2026 · quarter ended Jun 2026
Cash & equivalents falls 39.1% from a year ago
Cash & equivalents stood at $36.47M at the end of Q2 FY2026, down 39.1% from a year earlier and down 13.4% from the prior quarter. Over 3 fiscal years it compounded at -23.9% a year.
Context
- Cash & equivalents amounted to 90.8% of total assets at the end of Q2 FY2026, down 4.3 pp from a year earlier.
- Cash & equivalents increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -39.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 48M USD
- Year-over-year change
- -34.2%
- 4-year CAGR
- -11.4%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 48M | -34.2% |
| FY2024 | 2024-12-31 | 72.9M | -4.9% |
| FY2023 | 2023-12-31 | 76.68M | -29.6% |
| FY2022 | 2022-12-31 | 108.91M | +39.9% |
| FY2021 | 2021-12-31 | 77.83M | — |
Cash & Equivalents vs competitors
How ATNM compares with its peers on the latest reported figures
- ATNM's Jun 2026 cash & equivalents of $36.47M is the 3rd highest of the 5 companies compared; the peer median is $86M.
- Its year-over-year change of -39.1% is the 4th highest of 5, against a peer median of +16.4%.
- Cash & equivalents amounts to 90.8% of total assets for ATNM, versus a peer median of 89.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
OKUROnKure Therapeutics, Inc. | Mar 2026 | $192.11M | +98.7% | +72.3% | 96.7% |
| Mar 2026 | $150.33M | +68.8% | +4.5% | 92.0% | |
| Jun 2026 | $36.47M | -39.1% | -23.9% | 90.8% | |
| Mar 2026 | $21.66M | -45.8% | -28.7% | 87.8% | |
| Mar 2026 | $14.22M | -36.1% | -11.7% | 87.5% | |
| Peer median (excluding ATNM) | $86M | +16.4% | -3.6% | 89.9% | |
Competitors are the stored peer set for ATNM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 77.83M | 108.91M | 76.68M | 72.9M | 48M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 442K | 396K | 226K | 357K | 1.38M |
| Total Current Assets | 79.75M | 110.94M | 78.26M | 74.51M | 49.38M |
| Property, Plant & Equipment (Net) | 639K | 2.95M | 2.87M | 2.07M | 2.06M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 313K | 324K | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 0 | 302K | 0 | 0 | 335K |
| Total Non-current Assets | 639K | 3.25M | 3.18M | 2.39M | 2.39M |
| Total Assets | 80.39M | 114.19M | 81.45M | 76.9M | 51.78M |
| Account Payables | 5.54M | 10.13M | 7.95M | 7.57M | 0 |
| Short-term Debt | 0 | 0 | 541K | 0 | 722K |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 35M |
| Other Current Liabilities | 998K | 0 | 0 | 0 | (27.75M) |
| Total Current Liabilities | 6.84M | 10.63M | 8.49M | 8.15M | 7.97M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 35M | 35M | 35M |
| Other Non-current Liabilities | 0 | 35M | 0 | 0 | 0 |
| Total Non-current Liabilities | 3K | 37.08M | 36.57M | 35.99M | 35.97M |
| Total Liabilities | 6.84M | 47.71M | 45.07M | 44.14M | 43.94M |
| Common Stock | 22K | 26K | 28K | 31K | 31K |
| Retained Earnings | (255.75M) | (288.77M) | (337.58M) | (375.83M) | (409.71M) |
| Accumulated OCI | (0) | (0) | 0 | 0 | (20K) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 73.55M | 66.48M | 36.38M | 32.76M | 7.83M |
| Total Debt | 310K | 2.58M | 2.11M | 1.57M | 1.69M |
| Net Debt | (77.52M) | (106.33M) | (74.56M) | (71.33M) | (46.3M) |
Actinium Pharmaceuticals, Inc.
AMEX:ATNM
Intrinsic Alpha fair value
Locked
Current Price
$1.64
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.